$4000 | Single User
$8000 | Site License
$12000 | Enterprise License

Artificial Pancreas - Medical Devices Pipeline Assessment, 2017
[Report Updated: 01-08-2017]

Published by Global Data: 01 Aug 2017 | 111104 | In Stock
Related Topics: Medical Devices

Introduction

Artificial Pancreas - Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, “Artificial Pancreas - Medical Devices Pipeline Assessment, 2017" provides an overview of Artificial Pancreas currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Artificial Pancreas pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Artificial Pancreas under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Artificial Pancreas and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Artificial Pancreas under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents
for Artificial Pancreas - Medical Devices Pipeline Assessment, 2017 [Report Updated: 01-08-2017]

  • 1 Table of Contents

    1 Table of Contents 2

    1.1 List of Tables 5

    1.2 List of Figures 8

    2 Introduction 9

    2.1 Artificial Pancreas Overview 9

    3 Products under Development 10

    3.1 Artificial Pancreas - Pipeline Products by Stage of Development 10

    3.2 Artificial Pancreas - Pipeline Products by Territory 11

    3.3 Artificial Pancreas - Pipeline Products by Regulatory Path 12

    3.4 Artificial Pancreas - Pipeline Products by Estimated Approval Date 13

    3.5 Artificial Pancreas - Ongoing Clinical Trials 14

    4 Artificial Pancreas - Pipeline Products under Development by Companies 15

    4.1 Artificial Pancreas Companies - Pipeline Products by Stage of Development 15

    4.2 Artificial Pancreas - Pipeline Products by Stage of Development 17

    5 Artificial Pancreas Companies and Product Overview 19

    5.1 Admetsys Corporation Company Overview 19

    5.1.1 Admetsys Corporation Pipeline Products & Ongoing Clinical Trials Overview 19

    5.2 Advanced Biosensors-Ohio, Llc Company Overview 20

    5.2.1 Advanced Biosensors-Ohio, Llc Pipeline Products & Ongoing Clinical Trials Overview 20

    5.3 Animas Corp Company Overview 21

    5.3.1 Animas Corp Pipeline Products & Ongoing Clinical Trials Overview 21

    5.4 Beta Bionics Inc Company Overview 22

    5.4.1 Beta Bionics Inc Pipeline Products & Ongoing Clinical Trials Overview 22

    5.5 Beta-O2 Technologies Ltd Company Overview 25

    5.5.1 Beta-O2 Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 25

    5.6 Bigfoot Biomedical, Inc. Company Overview 28

    5.6.1 Bigfoot Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28

    5.7 BioTex Inc Company Overview 29

    5.7.1 BioTex Inc Pipeline Products & Ongoing Clinical Trials Overview 29

    5.8 Cerco Medical LLC Company Overview 30

    5.8.1 Cerco Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 30

    5.9 Converge Biotech, Inc. Company Overview 31

    5.9.1 Converge Biotech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31

    5.10 Covalor Medical, LLC Company Overview 32

    5.10.1 Covalor Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 32

    5.11 De Montfort University Company Overview 33

    5.11.1 De Montfort University Pipeline Products & Ongoing Clinical Trials Overview 33

    5.12 Debiotech SA Company Overview 34

    5.12.1 Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview 34

    5.13 Defymed Inc Company Overview 35

    5.13.1 Defymed Inc Pipeline Products & Ongoing Clinical Trials Overview 35

    5.14 Diabeloop Company Overview 36

    5.14.1 Diabeloop Pipeline Products & Ongoing Clinical Trials Overview 36

    5.15 Giner Inc Company Overview 39

    5.15.1 Giner Inc Pipeline Products & Ongoing Clinical Trials Overview 39

    5.16 Imperial College London Company Overview 40

    5.16.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 40

    5.17 Inreda Diabetic BV Company Overview 41

    5.17.1 Inreda Diabetic BV Pipeline Products & Ongoing Clinical Trials Overview 41

    5.18 Insulet Corp Company Overview 42

    5.18.1 Insulet Corp Pipeline Products & Ongoing Clinical Trials Overview 42

    5.19 Kencak LLC Company Overview 43

    5.19.1 Kencak LLC Pipeline Products & Ongoing Clinical Trials Overview 43

    5.20 Medtronic plc Company Overview 44

    5.20.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 44

    5.21 Miromatrix Medical Inc Company Overview 52

    5.21.1 Miromatrix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 52

    5.22 Nikkiso Co., Ltd. Company Overview 53

    5.22.1 Nikkiso Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53

    5.23 Pacific Diabetes Technologies, Inc. Company Overview 54

    5.23.1 Pacific Diabetes Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 54

    5.24 Pancreum, LLC Company Overview 55

    5.24.1 Pancreum, LLC Pipeline Products & Ongoing Clinical Trials Overview 55

    5.25 PharmaCyte Biotech Inc Company Overview 56

    5.25.1 PharmaCyte Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 56

    5.26 Polytechnic University of Valencia Company Overview 57

    5.26.1 Polytechnic University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 57

    5.27 Rensselaer Polytechnic Institute Company Overview 58

    5.27.1 Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview 58

    5.28 Schneider Children's Medical Center of Israel Company Overview 59

    5.28.1 Schneider Children's Medical Center of Israel Pipeline Products & Ongoing Clinical Trials Overview 59

    5.29 Senseonics Holdings, Inc. Company Overview 60

    5.29.1 Senseonics Holdings, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60

    5.30 TecMed, Inc. Company Overview 63

    5.30.1 TecMed, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63

    5.31 The University of Newcastle Company Overview 64

    5.31.1 The University of Newcastle Pipeline Products & Ongoing Clinical Trials Overview 64

    5.32 TypeZero Technologies LLC Company Overview 65

    5.32.1 TypeZero Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 65

    5.33 Ultradian Diagnostics LLC Company Overview 68

    5.33.1 Ultradian Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 68

    5.34 Universidad Autonoma de Madrid Company Overview 69

    5.34.1 Universidad Autonoma de Madrid Pipeline Products & Ongoing Clinical Trials Overview 69

    5.35 University of California San Francisco Company Overview 70

    5.35.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 70

    5.36 University of California Santa Barbara Company Overview 71

    5.36.1 University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 71

    5.37 University of Cambridge Company Overview 73

    5.37.1 University of Cambridge Pipeline Products & Ongoing Clinical Trials Overview 73

    5.38 University of Florida Company Overview 78

    5.38.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 78

    5.39 XERIS Pharmaceuticals Inc Company Overview 79

    5.39.1 XERIS Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 79

    6 Artificial Pancreas - Recent Developments 80

    6.1 Jul 26, 2017: PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer 80

    6.2 Jul 10, 2017: PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors 81

    6.3 Jun 26, 2017: Medtronic Announces Outcomes-Based Agreement with Aetna for Type 1 and Type 2 Diabetes Patients 82

    6.4 Jun 22, 2017: Phase 2a trial results support development of dasiglucagon in the iLet pump system for type 1 diabetes 82

    6.5 Jun 12, 2017: Insulet Presents Positive Omnipod Horizon Hybrid Closed-Loop Study Results in Children 84

    6.6 Jun 07, 2017: Medtronic Initiates U.S. Launch of World's First Hybrid Closed Loop System for Type 1 Diabetes 84

    6.7 May 30, 2017: Insulet Appoints Bret Christensen as Chief Commercial Officer 86

    6.8 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 86

    6.9 May 08, 2017: Insulet Reports First Quarter 2017 Financial Results 89

    6.10 May 02, 2017: PharmaCyte Biotech Appoints Thomas Yuen to Board of Directors 90

    6.11 Apr 28, 2017: Artificial pancreas benefits young children, trial shows 91

    6.12 Apr 20, 2017: Cellnovo announces that Diabeloop is launching a CE marking Registration Study on Artificial Pancreas with Cellnovo pump 91

    6.13 Apr 19, 2017: PharmaCyte Biotech Receives the 2017 “Pipelines of Promise” Award from BIO International 92

    6.14 Apr 03, 2017: PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development 93

    6.15 Mar 30, 2017: ConvaTec Expands Unomedical Manufacturing Technology Partnership with Medtronic Diabetes to Meet Growing Demand 94

    6.16 Mar 13, 2017: PharmaCyte Biotech Names Dr. Leonard Makowka as Senior Strategic Advisor 94

    6.17 Mar 06, 2017: Important Update On Minimed 670G Availability And The Priority Access Program 95

    6.18 Feb 27, 2017: Insulet Reports Fourth Quarter and Full Year 2016 Financial Results 96

    6.19 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 98

    6.20 Feb 17, 2017: Insulet Presents Strong Omnipod Horizon Hybrid Closed-Loop Study Results at ATTD in Paris 101

    6.21 Feb 13, 2017: National Institutes of Health Funds Schneider Children's Medical Center and International Diabetes Center Closed-Loop System Research 102

    6.22 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 103

    6.23 Jan 09, 2017: Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO 103

    6.24 Jan 05, 2017: Cellnovo and Diabeloop Update on Artificial Pancreas 104

    6.25 Dec 19, 2016: Bionic pancreas system successfully controls blood sugar without risk of hypoglycemia 105

    6.26 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 106

    6.27 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 109

    6.28 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 110

    6.29 Nov 03, 2016: Insulet Reports Third Quarter 2016 Financial Results 111

    6.30 Oct 19, 2016: Insulet Announces Board and Management Changes 112

    6.31 Sep 28, 2016: FDA approves first automated insulin delivery device for type 1 diabetes 112

    6.32 Sep 15, 2016: The Journal of the American Medical Association Publishes Medtronic's Hybrid Closed Loop System Pivotal Trial Results 113

    6.33 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 114

    6.34 Sep 13, 2016: Insulet Enrolls First Patients in Clinical Trial for its Omnipod Artificial Pancreas System 115

    6.35 Sep 06, 2016: Insulet to Establish Highly-Automated Manufacturing Operation in the United States 116

    6.36 Sep 06, 2016: Insulet Announces Executive Appointments 116

    6.37 Sep 05, 2016: Artificial pancreas trial in young children with diabetes receives €4.6millon grant from European Commission 117

    6.38 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 118

    7 Appendix 121

    7.1 Methodology 121

    7.2 About GlobalData 124

    7.3 Contact Us 124

    7.4 Disclaimer 124

List Of Tables
in Artificial Pancreas - Medical Devices Pipeline Assessment, 2017 [Report Updated: 01-08-2017]

1.1 List of Tables

Table 1: Artificial Pancreas - Pipeline Products by Stage of Development 10

Table 2: Artificial Pancreas - Pipeline Products by Territory 11

Table 3: Artificial Pancreas - Pipeline Products by Regulatory Path 12

Table 4: Artificial Pancreas - Pipeline Products by Estimated Approval Date 13

Table 5: Artificial Pancreas - Ongoing Clinical Trials 14

Table 6: Artificial Pancreas Companies - Pipeline Products by Stage of Development 15

Table 7: Artificial Pancreas - Pipeline Products by Stage of Development 17

Table 8: Admetsys Corporation Pipeline Products & Ongoing Clinical Trials Overview 19

Table 9: Admetsys Smart Pancreas - Product Status 19

Table 10: Admetsys Smart Pancreas - Product Description 19

Table 11: Advanced Biosensors-Ohio, Llc Pipeline Products & Ongoing Clinical Trials Overview 20

Table 12: Artificial Pancreas - Product Status 20

Table 13: Artificial Pancreas - Product Description 20

Table 14: Animas Corp Pipeline Products & Ongoing Clinical Trials Overview 21

Table 15: Hypoglycemia-Hyperglycemia Minimizer System - Product Status 21

Table 16: Hypoglycemia-Hyperglycemia Minimizer System - Product Description 21

Table 17: Beta Bionics Inc Pipeline Products & Ongoing Clinical Trials Overview 22

Table 18: iLet - Product Status 22

Table 19: iLet - Product Description 22

Table 20: Beta Bionics Inc - Ongoing Clinical Trials Overview 23

Table 21: iLet - A Multicenter Study of Outpatient Automated Blood Glucose Control with a Bihormonal Bionic Pancreas 24

Table 22: iLet - Closed-loop Glucagon Administration for the Automated Prevention and Treatment of Hypoglycemia 24

Table 23: Beta-O2 Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 25

Table 24: ßAir Bio-artificial Pancreas - Product Status 25

Table 25: ßAir Bio-artificial Pancreas - Product Description 25

Table 26: Beta-O2 Technologies Ltd - Ongoing Clinical Trials Overview 26

Table 27: ßAir Bio-artificial Pancreas - An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets within the Bioartificial Pancreas Beta-Air in Patients with Type 1 Diabetes Mellitus 27

Table 28: Bigfoot Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28

Table 29: Smartloop Automated Insulin Delivery System - Product Status 28

Table 30: Smartloop Automated Insulin Delivery System - Product Description 28

Table 31: BioTex Inc Pipeline Products & Ongoing Clinical Trials Overview 29

Table 32: Artificial Pancreas - Product Status 29

Table 33: Artificial Pancreas - Product Description 29

Table 34: Cerco Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 30

Table 35: Islet Sheet - Product Status 30

Table 36: Islet Sheet - Product Description 30

Table 37: Converge Biotech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31

Table 38: Bioartificial Pancreas System - Product Status 31

Table 39: Bioartificial Pancreas System - Product Description 31

Table 40: Covalor Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 32

Table 41: Artificial Pancreas - Product Status 32

Table 42: Artificial Pancreas - Product Description 32

Table 43: De Montfort University Pipeline Products & Ongoing Clinical Trials Overview 33

Table 44: InSmart Artificial Pancreas - Product Status 33

Table 45: InSmart Artificial Pancreas - Product Description 33

Table 46: Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview 34

Table 47: Next Generation Artificial Pancreas - Product Status 34

Table 48: Next Generation Artificial Pancreas - Product Description 34

Table 49: Defymed Inc Pipeline Products & Ongoing Clinical Trials Overview 35

Table 50: MAILPAN - Product Status 35

Table 51: MAILPAN - Product Description 35

Table 52: Diabeloop Pipeline Products & Ongoing Clinical Trials Overview 36

Table 53: Diabeloop Artificial Pancreas - Product Status 36

Table 54: Diabeloop Artificial Pancreas - Product Description 36

Table 55: Diabeloop - Ongoing Clinical Trials Overview 37

Table 56: Diabeloop Artificial Pancreas - Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop for Three Months at Home in Comparison with Conventional Treatment by External Insulin Pump in Patients with Type 1 Diabetes 38

Table 57: Giner Inc Pipeline Products & Ongoing Clinical Trials Overview 39

Table 58: BAPIOS System - Product Status 39

Table 59: BAPIOS System - Product Description 39

Table 60: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 40

Table 61: Bio-inspired Artificial Pancreas - Product Status 40

Table 62: Bio-inspired Artificial Pancreas - Product Description 40

Table 63: Inreda Diabetic BV Pipeline Products & Ongoing Clinical Trials Overview 41

Table 64: Bi-Hormonal Artificial Pancreas - Product Status 41

Table 65: Bi-Hormonal Artificial Pancreas - Product Description 41

Table 66: Insulet Corp Pipeline Products & Ongoing Clinical Trials Overview 42

Table 67: Omnipod Horizon Hybrid Closed Loop System - Product Status 42

Table 68: Omnipod Horizon Hybrid Closed Loop System - Product Description 42

Table 69: Kencak LLC Pipeline Products & Ongoing Clinical Trials Overview 43

Table 70: BioArtificial Pancreas - Product Status 43

Table 71: BioArtificial Pancreas - Product Description 43

Table 72: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 44

Table 73: MiniMed 640G System - Product Status 44

Table 74: MiniMed 640G System - Product Description 45

Table 75: MiniMed 670G - Product Status 45

Table 76: MiniMed 670G - Product Description 45

Table 77: Third-Generation Artificial Pancreas System - Product Status 46

Table 78: Third-Generation Artificial Pancreas System - Product Description 46

Table 79: Medtronic plc - Ongoing Clinical Trials Overview 47

Table 80: MiniMed 670G - A Crossover Study Comparing Two Automated Insulin Delivery System Algorithms (PID vs. PID + Fuzzy Logic) in Adolescents and Young Adults with Type 1 Diabetes 48

Table 81: MiniMed 670G - Clinical Startup of the 670G Closed Loop Insulin Delivery System 48

Table 82: MiniMed 670G - Effect of Hybrid Closed-loop Insulin Delivery on Glucose Counterregulation in Long Standing Type 1 Diabetes: A Proof of Concept, Mechanistic, Single-arm Clinical Trial 48

Table 83: MiniMed 670G - Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes -Single-arm, Single-center, in Clinic Study-The DREAMED Trail 49

Table 84: MiniMed 670G - Multi-center, Randomized, Adaptive, Controlled Trial in Adult and Pediatric Patients with Type 1 Diabetes Using Hybrid Closed Loop System at Home 49

Table 85: MiniMed 670G - Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects with Type 1 Diabetes 49

Table 86: MiniMed 640G System - An Open-label, Multi-center, Randomized, 2-period Cross-over Study to Assess the Efficacy and Safety of Closed Loop Insulin Delivery Using Diluted Insulin in Comparison with Closed Loop with Non-diluted Insulin Over 21 Days in Children with Type 1 Diabetes Aged 1 to 7 Years in the Home Setting 50

Table 87: MiniMed 640G System - An Open-label, Multicenter, Randomized, Single-period, Parallel Design Study to Assess the Effect of Closed Loop Insulin Delivery from Onset of Type 1 Diabetes in Youth on Residual Beta Cell Function Compared to Standard Insulin Therapy 50

Table 88: MiniMed 640G System - Evaluation of Two Different Glucose Monitoring Treatments and Their Impact on Time in Target, Sleep and Quality of Life in Children with Type 1 Diabetes and Primary Caregivers 51

Table 89: MiniMed 640G System - Study of MiniMed 640G Insulin Pump With SmartGuard in Prevention of Low Glucose Events in Adults With Type 1 Diabetes 51

Table 90: MiniMed 640G System - Study of Minimed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes at Risk of Severe Hypoglycemia 51

Table 91: Miromatrix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 52

Table 92: Miro Pancreas - Product Status 52

Table 93: Miro Pancreas - Product Description 52

Table 94: Nikkiso Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53

Table 95: Artificial Pancreas - Product Status 53

Table 96: Artificial Pancreas - Product Description 53

Table 97: Pacific Diabetes Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 54

Table 98: Artificial Endocrine Pancreas - Product Status 54

Table 99: Artificial Endocrine Pancreas - Product Description 54

Table 100: Pancreum, LLC Pipeline Products & Ongoing Clinical Trials Overview 55

Table 101: Genesis Artificial Pancreas - Product Status 55

Table 102: Genesis Artificial Pancreas - Product Description 55

Table 103: PharmaCyte Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 56

Table 104: Bio-Artificial Pancreas - Product Status 56

Table 105: Bio-Artificial Pancreas - Product Description 56

Table 106: Polytechnic University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 57

Table 107: ClosedLoop 4Meal Control - Product Status 57

Table 108: ClosedLoop 4Meal Control - Product Description 57

Table 109: Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview 58

Table 110: Closed-Loop Artificial Pancreas System - Product Status 58

Table 111: Closed-Loop Artificial Pancreas System - Product Description 58

Table 112: Schneider Children's Medical Center of Israel Pipeline Products & Ongoing Clinical Trials Overview 59

Table 113: MD-Logic Artificial Pancreas - Product Status 59

Table 114: MD-Logic Artificial Pancreas - Product Description 59

Table 115: Senseonics Holdings, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60

Table 116: Eversense CGM System Integrated With inControl And Accu-Chek Insight Insulin Pump - Product Status 60

Table 117: Eversense CGM System Integrated With inControl And Accu-Chek Insight Insulin Pump - Product Description 60

Table 118: Senseonics Holdings, Inc. - Ongoing Clinical Trials Overview 61

Table 119: Eversense CGM System Integrated With inControl And Accu-Chek Insight Insulin Pump - Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial Research Site Training Protocol 62

Table 120: Eversense CGM System Integrated With inControl And Accu-Chek Insight Insulin Pump - Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial: A Randomized Clinical Trial to Assess the Efficacy of Adjunctive Closed Loop Control Versus Sensor-augmented Pump Therapy in the Management of Type 1 Diabetes 62

Table 121: TecMed, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63

Table 122: TecMed Artificial Pancreas - Product Status 63

Table 123: TecMed Artificial Pancreas - Product Description 63

Table 124: The University of Newcastle Pipeline Products & Ongoing Clinical Trials Overview 64

Table 125: Closed Glucose-Sensing Insulin-Delivery System - Product Status 64

Table 126: Closed Glucose-Sensing Insulin-Delivery System - Product Description 64

Table 127: TypeZero Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 65

Table 128: inControl - Product Status 65

Table 129: inControl - Product Description 65

Table 130: TypeZero Technologies LLC - Ongoing Clinical Trials Overview 66

Table 131: inControl - Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial Research Site Training Protocol 67

Table 132: inControl - Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial: A Randomized Clinical Trial to Assess the Efficacy of Adjunctive Closed Loop Control Versus Sensor-augmented Pump Therapy in the Management of Type 1 Diabetes 67

Table 133: inControl - Examination of New Control Algorithm of inControl AP 67

Table 134: Ultradian Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 68

Table 135: Artificial Pancreas - Product Status 68

Table 136: Artificial Pancreas - Product Description 68

Table 137: Universidad Autonoma de Madrid Pipeline Products & Ongoing Clinical Trials Overview 69

Table 138: Predictive Rule-Based Algorithm - Product Status 69

Table 139: Predictive Rule-Based Algorithm - Product Description 69

Table 140: University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 70

Table 141: Bioartificial Pancreas - Product Status 70

Table 142: Bioartificial Pancreas - Product Description 70

Table 143: University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 71

Table 144: Closed-Loop Artificial Pancreas - Product Status 71

Table 145: Closed-Loop Artificial Pancreas - Product Description 71

Table 146: Pediatric Artificial Pancreas - Product Status 72

Table 147: Pediatric Artificial Pancreas - Product Description 72

Table 148: University of Cambridge Pipeline Products & Ongoing Clinical Trials Overview 73

Table 149: Artificial Pancreas - Product Status 73

Table 150: Artificial Pancreas - Product Description 73

Table 151: Florence D2A System - Product Status 74

Table 152: Florence D2A System - Product Description 74

Table 153: University of Cambridge - Ongoing Clinical Trials Overview 75

Table 154: Florence D2A System - Closing the Loop in Adults with Type 1 Diabetes and HbA1C Less than 7.5% Under Free Living Conditions 76

Table 155: Artificial Pancreas - An Open-label, Multi-center, Randomized, 2-period Cross-over Study to Assess the Efficacy and Safety of Closed Loop Insulin Delivery Using Diluted Insulin in Comparison with Closed Loop with Non-diluted Insulin Over 21 Days in Children with Type 1 Diabetes Aged 1 to 7 Years in the Home Setting 77

Table 156: University of Florida Pipeline Products & Ongoing Clinical Trials Overview 78

Table 157: Bioartificial Pancreas - Type 1 Diabetes - Product Status 78

Table 158: Bioartificial Pancreas - Type 1 Diabetes - Product Description 78

Table 159: XERIS Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 79

Table 160: G-Pump - BP - Product Status 79

Table 161: G-Pump - BP - Product Description 79

Table 162: Glossary 123

List Of Figures, Charts and Diagrams
in Artificial Pancreas - Medical Devices Pipeline Assessment, 2017 [Report Updated: 01-08-2017]

1.2 List of Figures

Figure 1: Artificial Pancreas - Pipeline Products by Stage of Development 10

Figure 2: Artificial Pancreas - Pipeline Products by Territory 11

Figure 3: Artificial Pancreas - Pipeline Products by Regulatory Path 12

Figure 4: Artificial Pancreas - Pipeline Products by Estimated Approval Date 13

Figure 5: Artificial Pancreas - Ongoing Clinical Trials 14

Additional Details

Publisher

Global Data

Publisher Information

Reference

111104 | GDME0399EPD

Number of Pages

124

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Sugar-Based Excipients Market by Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), Type (Powder/Granule, Crystal, Syrup), Functionality (Filler & Diluent, Tonicity Agents), Formulation (Oral, Topical, Parenteral) - Global Forecast to 2021
The global sugar excipients market is estimated to grow at a CAGR of 4.3% from 2016 to 2021, to reac...
08 Dec 2016 by MarketsandMarkets USD $5,650 More Info
Total Artificial Heart - Medical Devices Pipeline Assessment, 2016
Total Artificial Heart - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's Medical Device...
01 Jun 2016 by Global Data USD $2,500 More Info
Total Artificial Heart - Medical Devices Pipeline Assessment, 2016
Total Artificial Heart - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's Medical Device...
01 Jun 2016 by Global Data USD $2,500 More Info
Artificial Disc Replacement Systems - Medical Devices Pipeline Assessment, 2016
Artificial Disc Replacement Systems - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's M...
11 Mar 2016 by Global Data USD $4,000 More Info
Artificial Pancreas - Medical Devices Pipeline Assessment, 2016
Artificial Pancreas - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's Medical Devices s...
11 Mar 2016 by Global Data USD $4,000 More Info
North America Unsaturated Polyester Resin Market By Type, By Application (Building & Construction, Marine, Automotive & Transportation, Pipes & Tanks, Electrical & Electronics, Wind Energy, Artificial Stones), By Geography– Analysis & Forecast to 2020
Unsaturated polyester resins (UPR) are highly durable, when they are cross linked with monomers such...
01 Oct 2015 by MicroMarketMonitor USD $2,650 More Info
Middle East Well Intervention Market by Service Type (Logging & Bottom Hole Survey, Tubing/Packer Failure & Repair, Stimulation, Artificial Lift, Others), Application (Onshore & Offshore), & Country - Analysis & Forecast to 2019
Well intervention services are required throughout the lifespan of an oil & gas well. Worldwide incr...
13 May 2015 by MarketsandMarkets USD $2,650 More Info
Asia Pacific Well Intervention Market by Service Type (Logging & Bottom Hole Survey, Tubing/Packer Failure & Repair, Stimulation, Artificial Lift, Others), by Application (Onshore & Offshore), and by Country - Analysis & Forecast To 2019
Asia-Pacific well intervention services market is estimated to grow at a CAGR of 3.5% from 2014 to 2...
07 May 2015 by MarketsandMarkets USD $2,650 More Info
North America Well Intervention Market by Service Types (Logging & Bottom Hole Survey, Tubing/Packer Failure & Repair, Stimulation, Artificial Lift, Others), By Application (Onshore & Offshore), and By Countries – Analysis & Forecast to 2019
The North America well intervention market constitutes 50% of the global Well Intervention market, a...
02 May 2015 by MarketsandMarkets USD $2,650 More Info
Africa Well Intervention Service Market by Types (Logging & Bottom Hole Survey, Tubing/Packer Failure & Repair, Stimulation, Artificial Lift, Others), by Application (Onshore & Offshore), and by Countries - Analysis and Forecast to 2019
The well intervention services market is estimated to grow at a CAGR of 4% from 2014 to 2019. Geogra...
28 Apr 2015 by MarketsandMarkets USD $2,650 More Info

This report is published by Global Data

Download Free Report Summary PDF

Artificial Pancreas - Medical Devices Pipeline Assessment, 2017 [Report Updated: 01-08-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...